MALVERN, PA (October 22, 2013) – PuriCore (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announced the launch of NovaZo™ Animal Health Wound Irrigation Solution at the upcoming 2013 American College of Veterinarian Surgeons (ACVS) Symposium, to be held October 24 to 26 in San Antonio, TX. This new animal health product is based on PuriCore’s Vashe Wound Therapy products for humans, which have been FDA-cleared and on the market for five years. NovaZo is a safe and effective wound cleanser for use on companion and large animals of all species including competitive animals. Currently, NovaZo is available through veterinarians in the US and will be available internationally later in 2013.
NovaZo is used in the management of post-surgical incisions; moist dressings; hot spots, bites, and rashes; burn, graft, and flap dressings; and for debridement irrigation and odor control. It can be dispensed for home and farm use. It is safe for use around an animal’s mouth, nose, eyes, and ears and is non-cytotoxic, nonstinging, and steroid-free. NovaZo will be sold direct by PuriCore in 12-packs of 475-ml bottles. The list price of NovaZo is $39.99 per bottle ($479.88 per case). PuriCore will also continue to pursue partnering discussions both in the US and internationally. More information on NovaZo is available at www.novazo.com.
“NovaZo is a breakthrough for wound management in all animals—from cats, dogs, and exotic pets to horses and cattle and even competitive animals,” said Michael Ashton, PuriCore Executive Chairman. “In early market testing, veterinarians found that this one-step product to be very versatile, easy to use in the clinic as well as at home and on farms as directed, and very safe for the animals even when used around the most sensitive areas.”
“In my clinical use of NovaZo, I am impressed with the amount of debris that comes off the wound without my having to touch it,” said Frank H. Welker, DVM, MS, The Ohio State University College of Veterinary Medicine. “NovaZo has a high concentration of HOCl and is hypochlorite-free, making it skin-friendly and noncytotoxic. This, in comparison to potentially cytotoxic solutions containing povidone-iodine, chlorhexadine, and hypochlorite, represents a novel advancement in animal wound care.”
Contact:
Sage Strategic Marketing
Jennifer Guinan
+1 610.410.8111
jennifer@sagestrat.com
About PuriCore
PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore’s antimicrobial technology and complementary products are used in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients and staff in UK hospitals. PuriCore’s breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. In the Food & Agriculture market, PuriCore’s portfolio is used by three of the top-five US supermarket retailers to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing its research and development programs on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forwardlooking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Help employers find you! Check out all the jobs and post your resume.
